Table 1.
Baseline ophthalmic characteristics in eyes with uveitic macular edema.
| Baseline characteristics | |
|---|---|
| Eyes/Patients (n/n) | 60/60 |
| Evolution time to baseline (months, mean ± SD) | 17 ± 31 |
| Follow-up (months) | 12 |
| Age (years, mean ± SD) | 51 ± 15 |
| Female, n (%) | 35 (58.3) |
| Bilateral, n (%) | 23 (38.3) |
| Patterns of UME1 | |
| Cystoid, n (%) | 47 (78.3) |
| Diffuse, n (%) | 14 (23.3) |
| Subretinal fluid, n (%) | 21 (35) |
| Tractional component2, n (%) | 18 (30) |
| Anatomical classification (SUN) | |
| Anterior, n (%) | 16 (26.6) |
| Intermediate, n (%) | 9 (15) |
| Posterior, n (%) | 22 (36.7) |
| Panuveitis, n (%) | 13 (21.7) |
| Etiologic classification | |
| Unclassifiable (undifferentiated), n (%) | 15 (25) |
| Seronegative spondyloarthropathies, n (%) | 12 (20) |
| Ankylosing spondylitis, n | 6 |
| HLA-B27 + (without SA), n | 3 |
| Inflammatory bowel disease, n | 1 |
| Psoriatic arthritis, n | 1 |
| Reactive arthritis, n | 1 |
| White dot syndromes,n (%) | 14 (23.3) |
| Birdshot, n | 13 |
| Serpiginous, n | 1 |
| Other etiologies, n (%) | 19 (31.6) |
| Sarcoidosis, n | 6 |
| Vogt-Koyanagi-Harada, n | 5 |
| Juvenile idiopathic arthritis | 2 |
| Multiple sclerosis, n | 2 |
| Pars planitis, n | 2 |
| Sympathetic ophthalmia, n | 1 |
| IRVAN, n | 1 |
| Treatment/s for UME1 | |
| Topical, n (%) | 2 (3.3) |
| Local (only), n (%) | 14(23.3) |
| TCA (peri/intraocular), n | 5 |
| Dexamethasone implant, n | 11 |
| Systemic ± local, n (%) | 40 (66.7) |
| Oral Corticosteroids, n | 37 |
| Classic Immunomodulators, n | 19 |
| Biologics, n | 13 |
| Previous vitrectomy, n (%) | 2 (3.3) |
1One eye may belong to more than one category (four eyes did not receive any treatment). 2It refers to qualitatively thickened vitreo-macular interface.
UME, uveitis macular edema; SUN, standardization of uveitis nomenclature classification; SA, spondyloarthropaties; IRVAN, idiopathic retinal vasculitis, aneurisms and neuroretinitis syndrome; TCA, triamcinolone acetonide injections.